ホーム Mitochondria-targeted antioxidants for treatment of Parkinson’s disease: preclinical and clinical outcomes.
臨床水素治療研究会事務局
2016年2月19日
Jin H*, Kanthasamy A*, Ghosh A*, Anantharam V*, Kalyanaraman B†, Kanthasamy AG‡.
*Parkinson’s Disorder Research Laboratory, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, USA.
†Department of Biophysics, Free Radical Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
‡Parkinson’s Disorder Research Laboratory, Iowa Center for Advanced Neurotoxicology, Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, USA. Electronic address
前の記事
Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies.
次の記事
Vitamin D protects human endothelial cells from H₂O₂ oxidant injury through the Mek/Erk-Sirt1 axis activation.
